|
|
|
| Effect of Ivabradine Combined with Fuling Wenshen Capsule on Chronic Heart Failure Treatment |
| WANG Yi-lei, GAO Xin, LI Ya-feng, et al |
| The First Hospital of Yulin,Yulin 719000,Shaanxi |
|
|
|
|
Abstract 【Objective】To explore the effect of ivabradine and Fuling Wenshen capsule in the treatment of patients with chronic heart failure. 【Methods】A total of 116 patients with chronic heart failure in our hospital from December 2018 to January 2021 were selected. According to the random number table method, they were divided into the observation group and the control group, with 58 cases in each group. On the basis of conventional treatment, the control group was treated with ivabradine for 4 weeks, and the observation group was treated with ivabradine combined with Fuling Wenshen capsule for 4 weeks. The clinical efficacy, adverse reactions, and Lee's heart failure scores before treatment, 2 weeks, and 4 weeks after treatment, Minnesota living with heart failure questionnaire (MLHFQ) score, 6-min walking distance (6MWT), cardiac function indexes [left ventricular ejection fraction (LVEF), cardiac output (CO), stroke volume (SV)], Bax and Caspase-3 protein expression were compared between the two groups. 【Results】After 4 weeks of treatment, the total effective rate in the observation group was 93.10% (54/58), which was lower than 79.31% (46/58) in the control group. The difference was statistically significant (χ2=4.64, P<0.05). Compared to before treatment, Lee's heart failure score and MLHFQ score of the two groups were significantly reduced after 4 weeks of treatment, and 6MWT was significantly increased. The improvement in the observation group was better than the control group; and the difference was statistically significant (P<0.05). After 4 weeks of treatment, the levels of LVEF, CO and SV in the two groups were significantly higher than those before treatment; And the observation group increased better than the control group, the difference was statistically significant (P<0.05). The expression of Bax and Caspase-3 in the two groups showed a decreasing trend if comparing to before treatment, and the observation group was lower than the control group (P<0.05). 【Conclusion】The combination of ivabradine and Fuling Wenshen capsule in the treatment of chronic heart failure has a significant clinical effect and good safety. It can effectively control the symptoms of heart failure in patients, improve exercise endurance and quality of life, and at the same time alleviate myocardial cell damage, reduce apoptosis, and improve cardiac function.
|
|
Received: 19 April 2021
|
|
|
|
|
|
[1] THANDAVARAYAN R A,CHITTURI K R,GUHA A.Pathophysiology of Acute and Chronic Right Heart Failure[J].Cardiol Clin,2020,38(2):149-160.
[2] 李琳,莫卿,莫婷,等.老年慢性心力衰竭患者临床特征和药物治疗状况多中心回顾性分析[J].中华医学杂志,2018,98(9):673-677.
[3] 许彦倩,王登峰.伊伐布雷定联合参松养心胶囊对老年慢性心力衰竭患者的疗效及对血脂代谢、脑钠肽和心功能的影响[J].中国老年学杂志,2020,40(23):4932-4934.
[4] 张碧华,杨莉萍,唐鹏.慢性心力衰竭与中医相关病症的渊源与发展[J].中国中西医结合杂志,2018,38(5):633-635.
[5] 张松,廖宪勇,李白雪.中医治疗慢性心力衰竭的症候分析[J].四川中医,2020,38(2):208-211.
[6] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
[7] 国家中医药管理局医政司.中医病证诊断疗效标准[M].北京:中国中医药出版社,2017:30.
[8] SKRZYPEK A,MOSTOWIK M,SZELIGA M,et al.Chronic heart failure in the elderly:still a current medical problem[J].Folia Med Cracov,2018,58(4):47-56.
[9] 张婉秋,严光.老年慢性心衰患者生存质量影响因素及健康需求分析[J].系统医学,2020,5(7):55-58.
[10] 彭玉霞,卢桂林,张斌霞.中医药治疗慢性心力衰竭的研究进展[J].中国中医急症,2020,29(2):373-376.
[11] 王琦.参松养心胶囊联合伊伐布雷定治疗慢性心力衰竭的临床研究[J].现代药物与临床,2020,35(7):1398-1402.
[12] 杨温藤,林小君,郑毅.伊伐布雷定治疗慢性心力衰竭的临床疗效及对血流动力学、血管内皮功能、炎性因子的影响[J].中国卫生检验杂志,2019,29(3):337-340,350.
[13] 曲苗,庄颖梅,常惟智,等.基于网络药理学探索真武汤治疗慢性心力衰竭作用机制研究[J].辽宁中医药大学学报,2020,22(6):84-90.
[14] 吕俊芳,张宝霞.益气活血利水方治疗冠状动脉粥样硬化性心脏病慢性心力衰竭心肾阳虚证临床研究[J].中医学报,2018,33(1):133-137.
[15] 王楠.心脉隆注射液联合西药对慢性心力衰竭病人心功能及心肌损害的影响[J].中西医结合心脑血管病杂志,2019,17(16):2483-2486.
[16] JEELANI R,CHATZICHARALAMPOUS C,KOHAN-GHADR H R,et al.Hypochlorous acid reversibly inhibits caspase-3:a potential regulator of apoptosis[J].Free Radic Res,2020,54(1):43-56. |
|
|
|
2021, Vol. 38 
